To further investigate MET as a mechanism of resistance to rociletinib, we identified an expanded cohort of 16 patients with T790M-mutant tumours participating in rociletinib trials who had MET copy-number gain detected in pre-treatment biopsies or plasma (Methods). Here, MET is linked to neoplasm.